In this issue of Cancer Cell, Li et al. show that Candida albicans and Fusobacterium nucleatum form a cross-kingdom interaction through Flo9-RadD binding that accelerates colorectal cancer (CRC) progression. Disrupting this interaction with L-arginine reduces tumor burden, highlighting targeting microbial cooperation as a potential therapeutic strategy for CRC.
Cancer Cell published a clinical update in Oncology on 26 Mar 2026. The item focuses on A cross-kingdom alliance driving colorectal cancer. Open the detail page to review the full original feed content.